Trethera News

Gloved hand of a scientist in a lab writing on a digital stilus with a digital pen.Blue DNA illustrationPhoto of a series of test tubes.Scientific microscope with visual representation of DNA helix

Trethera Scientific Founder Dr. Caius Radu To Present Research At Los Angeles Bioscience Ecosystem Summit 2022

May 19, 2022

Dr. Caius Radu, Trethera’s scientific founder and UCLA professor, will present TRE‑515’s first‑in‑human deoxycytidine kinase inhibitor research at LABEST 2022. The presentation highlights TRE‑515’s dual potential in cancer and autoimmune disease treatment.

Read More

Trethera Announces Completion of $3.8 Million Seed Funding Round From Current Investors

May 11, 2022

Trethera closed a $3.8M follow-on seed funding from current investors to fuel its clinical-stage programs, including TRE‑515’s orphan-designated development in oncology and autoimmune conditions like MS and optic neuritis.

Read More

Trethera Announces Prostate Cancer Poster Presentation At The American Association For Cancer Research Annual Meeting

March 22, 2022

Trethera will showcase a poster at the AACR Annual Meeting where Dr. Caius Radu (UCLA) will present preclinical findings showing TRE‑515, a dCK inhibitor, selectively blocks prostate cancer growth in xenograft mouse models by depriving tumors of necessary DNA precursors.

Read More

Safety Review Committee Advances Trethera Phase 1 Solid Tumors Trial to Next Dose After First Patient Cohort Achieves Primary Endpoint

December 9, 2021

Trethera announced that its Phase 1a solid tumor dose escalation trial of TRE‑515 is advancing to the second dose level after the first patient cohort completed full dosing with no serious adverse events, earning unanimous approval from the independent Safety Review Committee.

Read More

Trethera Announces FDA Orphan Drug Designation Granted to TRE-515 for the Treatment of Demyelinating Optic Neuritis

November 12, 2021

Trethera announced that the FDA has granted Orphan Drug Designation to TRE‑515 for optic neuritis, a rare autoimmune disease causing vision loss. The designation complements existing ADEM orphan status and offers clinical trial and regulatory advantages.

Read More